Profil
Pieter Oldenziel has worked as a Director at Ablynx NV since 2019 and currently holds a position as Managing Director at Sanofi Foreign Participations BV.
Postes actifs de Pieter Oldenziel
| Sociétés | Poste | Début |
|---|---|---|
| ABLYNX | Director/Board Member | 01/01/2019 |
Sanofi Foreign Participations BV
 Sanofi Foreign Participations BV Pharmaceuticals: GenericHealth Technology Part of Sanofi, Sanofi Foreign Participations BV is a Dutch company that manufactures human monoclonal antibody drugs. The private company is based in Amsterdam, Netherlands. The company was founded in 1998. The CEO is Pieter Oldenziel. | Chief Executive Officer | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Sanofi Foreign Participations BV
Sanofi Foreign Participations BV Pharmaceuticals: GenericHealth Technology Part of Sanofi, Sanofi Foreign Participations BV is a Dutch company that manufactures human monoclonal antibody drugs. The private company is based in Amsterdam, Netherlands. The company was founded in 1998. The CEO is Pieter Oldenziel. | Health Technology |
